MAP3K5 and metabolic dysfunction-associated steatohepatitis: Clinical studies targeting genes associated with pro-inflammatory pathways, such as apoptosis signaling kinase-1 (ASK1) and C-C motif chemokine receptor 2 (CCR2)30–32, have been shown to improve NASH and control the progression of fibrosis, and there is great interest in the identification of additional inflammatory targets for potential therapies.